An open-trial evaluation of mitoxantrone in the treatment of progressive MS.
We treated 13 patients with progressive MS with mitoxantrone. All patients received a standard IV dose of mitoxantrone (8 mg/m2) every 3 weeks for a total of seven infusions, with dosage adjustments depending on the hematologic profile at the nadir. The treatment was well tolerated, with the most co...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1993
|
| _version_ | 1797058279295156224 |
|---|---|
| author | Noseworthy, J Hopkins, M Vandervoort, M Karlik, S Lee, D Penman, M Rice, G Grinwich, K Cauvier, H Harris, B |
| author_facet | Noseworthy, J Hopkins, M Vandervoort, M Karlik, S Lee, D Penman, M Rice, G Grinwich, K Cauvier, H Harris, B |
| author_sort | Noseworthy, J |
| collection | OXFORD |
| description | We treated 13 patients with progressive MS with mitoxantrone. All patients received a standard IV dose of mitoxantrone (8 mg/m2) every 3 weeks for a total of seven infusions, with dosage adjustments depending on the hematologic profile at the nadir. The treatment was well tolerated, with the most common side effect being mild nausea. Four of seven women developed transient secondary amenorrhea. The postenrollment clinical behavior of these patients was generally more favorable than during the 18 months prior to enrollment (only three of 13 patients developed an increase in the Expanded Disability Status Scale of more than 0.5 points), suggesting a possible treatment effect, but comparison with two historical control groups (both the active and placebo groups from the Canadian Cooperative Trial of Cyclophosphamide and Plasma Exchange) does not suggest that mitoxantrone was efficacious. Eight of 12 patients had evidence of MRI activity on 13 of 29 follow-up visits. This small, open-labeled pilot study did not provide strong support for proceeding with a randomized, controlled trial of this dosage regimen of mitoxantrone in patients with progressive MS. |
| first_indexed | 2024-03-06T19:48:13Z |
| format | Journal article |
| id | oxford-uuid:23112c42-585d-48ea-a575-4471ce0064f1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:48:13Z |
| publishDate | 1993 |
| record_format | dspace |
| spelling | oxford-uuid:23112c42-585d-48ea-a575-4471ce0064f12022-03-26T11:42:12ZAn open-trial evaluation of mitoxantrone in the treatment of progressive MS.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:23112c42-585d-48ea-a575-4471ce0064f1EnglishSymplectic Elements at Oxford1993Noseworthy, JHopkins, MVandervoort, MKarlik, SLee, DPenman, MRice, GGrinwich, KCauvier, HHarris, BWe treated 13 patients with progressive MS with mitoxantrone. All patients received a standard IV dose of mitoxantrone (8 mg/m2) every 3 weeks for a total of seven infusions, with dosage adjustments depending on the hematologic profile at the nadir. The treatment was well tolerated, with the most common side effect being mild nausea. Four of seven women developed transient secondary amenorrhea. The postenrollment clinical behavior of these patients was generally more favorable than during the 18 months prior to enrollment (only three of 13 patients developed an increase in the Expanded Disability Status Scale of more than 0.5 points), suggesting a possible treatment effect, but comparison with two historical control groups (both the active and placebo groups from the Canadian Cooperative Trial of Cyclophosphamide and Plasma Exchange) does not suggest that mitoxantrone was efficacious. Eight of 12 patients had evidence of MRI activity on 13 of 29 follow-up visits. This small, open-labeled pilot study did not provide strong support for proceeding with a randomized, controlled trial of this dosage regimen of mitoxantrone in patients with progressive MS. |
| spellingShingle | Noseworthy, J Hopkins, M Vandervoort, M Karlik, S Lee, D Penman, M Rice, G Grinwich, K Cauvier, H Harris, B An open-trial evaluation of mitoxantrone in the treatment of progressive MS. |
| title | An open-trial evaluation of mitoxantrone in the treatment of progressive MS. |
| title_full | An open-trial evaluation of mitoxantrone in the treatment of progressive MS. |
| title_fullStr | An open-trial evaluation of mitoxantrone in the treatment of progressive MS. |
| title_full_unstemmed | An open-trial evaluation of mitoxantrone in the treatment of progressive MS. |
| title_short | An open-trial evaluation of mitoxantrone in the treatment of progressive MS. |
| title_sort | open trial evaluation of mitoxantrone in the treatment of progressive ms |
| work_keys_str_mv | AT noseworthyj anopentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT hopkinsm anopentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT vandervoortm anopentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT karliks anopentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT leed anopentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT penmanm anopentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT riceg anopentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT grinwichk anopentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT cauvierh anopentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT harrisb anopentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT noseworthyj opentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT hopkinsm opentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT vandervoortm opentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT karliks opentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT leed opentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT penmanm opentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT riceg opentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT grinwichk opentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT cauvierh opentrialevaluationofmitoxantroneinthetreatmentofprogressivems AT harrisb opentrialevaluationofmitoxantroneinthetreatmentofprogressivems |